<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[elan Resources | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/elan.html]]></link>
	<description><![CDATA[White papers, case studies, business articles, and blog posts relating to elan]]></description>
	<s:counts start="0" returned="20" found="42" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Elan pins hopes on multiple sclerosis drug]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2Ffd2171c2-be09-11de-9195-00144feab49a.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake in the business to Johnson & Johnson last month.Tysabri, which accounts for two-thirds of group turnover, saw sales jump 19 per...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Wed, 21 Oct 2009 09:04:46 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/research+%2526+development.html"><![CDATA[Research & Development]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/divestment.html"><![CDATA[Divestment]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/health+%2526+healthcare.html"><![CDATA[Health & Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/interim+results.html"><![CDATA[Interim Results]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/results.html"><![CDATA[Results]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">JNJ</category>
	</item>
	<item>
		<title><![CDATA[Elan dealt a blow with Biogen ruling]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fwww.ft.com%2Fcms%2Fs%2F0%2F075b8c00-98e8-11de-aa1b-00144feabdc0.html&siteid=23&tag=financialtimes]]></link>
		<description><![CDATA[ Elan, the Irish domiciled pharmaceuticals company, suffered a sharp setback in its recapitalisation plans when a US judge ruledon Thursday that a planned $1.5bn deal with Johnson & Johnson violated the terms of an existing partnership with Biogen Idec.Deborah Batts, a Manhattan federal court judge, ruled that Elan had...]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<pubDate>Thu, 03 Sep 2009 17:46:20 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/johnson+%2526+johnson.html"><![CDATA[Johnson & Johnson]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/tysabri.html"><![CDATA[Tysabri]]></category>
		<category domain="http://resources.bnet.com/topic/business+structures.html"><![CDATA[Business Structures]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/company+news.html"><![CDATA[Company News]]></category>
		<category domain="http://resources.bnet.com/topic/contracts+%2526+new+orders.html"><![CDATA[Contracts & New Orders]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+finance.html"><![CDATA[Corporate Finance]]></category>
		<category domain="http://resources.bnet.com/topic/general+news.html"><![CDATA[General News]]></category>
		<category domain="http://resources.bnet.com/topic/health+%2526+healthcare.html"><![CDATA[Health & Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/restructuring.html"><![CDATA[Restructuring]]></category>
		<category domain="http://resources.bnet.com/topic/strategy.html"><![CDATA[Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/financial+times.html"><![CDATA[Financial Times]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">JNJ</category>
		<category domain="tickers">BIIB,JNJ</category>
	</item>
	<item>
		<title><![CDATA[Judge Orders Elan CEO Submit to Interrogation by Biogen Lawyers]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003993/judge-orders-elan-ceo-submit-to-interrogatation-by-biogen-lawyers/]]></link>
		<description><![CDATA[Elan's spat with Biogen over the rights to Tysabri seems likely to end up with Elan CEO Kelly Martin in a deposition with Biogen's lawyers, according to papers filed in litigation between the two companies. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 31 Aug 2009 08:07:55 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Elan Stock Keeps Rising Despite Denial of BMS Takeover]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002460/elan-stock-keeps-rising-despite-denial-of-bms-takeover/]]></link>
		<description><![CDATA[Elan's stock continues to float on the idea that BMS is about to buy some or all of the company. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 02 Jun 2009 08:04:17 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/denial.html"><![CDATA[Denial]]></category>
		<category domain="http://resources.bnet.com/topic/takeover.html"><![CDATA[Takeover]]></category>
		<category domain="http://resources.bnet.com/topic/elan+stock.html"><![CDATA[Elan Stock]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Elan Silent on Corporate Jets as 230 Are Laid Off]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001182/elan-silent-on-corporate-jets-as-230-are-laid-off/]]></link>
		<description><![CDATA[The 230 people being laid off by Elan Pharmaceuticals as part of its "further alignment of resources" and "on-going strategic review process" might want to ask whether Elan's three corporate jets are being laid off too.    Elan's use of corporate jets is an issue for Jack Schuler,...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Thu, 26 Feb 2009 14:14:33 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/jet.html"><![CDATA[Jet]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/workforce+management.html"><![CDATA[Workforce Management]]></category>
		<category domain="http://resources.bnet.com/topic/human+resources.html"><![CDATA[Human Resources]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Elan Management Creates Self-Enrichment Plan as Pfizer-Wyeth Deal Threatens Bapineuzumab]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10001034/elan-management-create-self-enriching-plan-as-pfizer-wyeth-deal-threatens-bapineuzumab/]]></link>
		<description><![CDATA[UPDATE: Elan says theÂ  share awards are part of "the normal annual compensation process" at Elan. See Elan's full statement in the comments section below.     Elan's senior management have hatched a plan to enrich themselves in the event of a sale or takeover of their troubled...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 17 Feb 2009 13:57:50 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/mergers+%2526+acquisitions.html"><![CDATA[Mergers & Acquisitions]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/investment.html"><![CDATA[Investment]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">PFE,WYE</category>
	</item>
	<item>
		<title><![CDATA[Elan Chairman: "We're Qualified Managers Because We're Irish'']]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000915/elan-chairman-were-qualified-to-run-this-drug-company-because-were-irish/]]></link>
		<description><![CDATA[Angry investor Jack Schuler is firing at Elan once again. The FT reports he's trying to block the sale of 19-25 percent of the company to outside investors. Roche is reportedly interested. Instead, Schuler wants Elan's management replaced with people who actually have experience in commercializing drugs.   ...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 09 Feb 2009 10:43:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/board.html"><![CDATA[Board]]></category>
		<category domain="http://resources.bnet.com/topic/chairman.html"><![CDATA[Chairman]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[Investor]]></category>
		<category domain="http://resources.bnet.com/topic/ceo.html"><![CDATA[CEO]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/financial+accounting.html"><![CDATA[Financial Accounting]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Elan Sees Problems on Alzheimer's Drug; Puts Itself Up for Sale]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000597/elan-sees-problems-on-alzheimers-drug-puts-itself-up-for-sale/]]></link>
		<description><![CDATA[Elan, the troubled Irish pharma company, has put itself up for sale just as it emerged that it will spend another six months testing bapineuzumab, its experimental Alzheimer's treatment. The drug has previously been linked to brain swelling in some patients. The sale raises the possibility that Elan's bizarre managers...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 14 Jan 2009 06:02:24 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/bapineuzumab.html"><![CDATA[Bapineuzumab]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Elan "Poison Pill" Deal With Biogen Prevents Rumored Pfizer Takeover]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000583/elan-poison-pill-deal-with-biogen-prevents-rumored-pfizer-takeover/]]></link>
		<description><![CDATA[Elan ended a rally in its stock last week when CEO Kelly Martin said the company was NOT negotiating to sell itself to Pfizer. Oddly, most coverage of the event -- the rumor-fueled stock runup and the bursting of Elan's bubble -- didn't mention the reason why Kelly was so...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 12 Jan 2009 10:47:08 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/poison+pill.html"><![CDATA[Poison Pill]]></category>
		<category domain="http://resources.bnet.com/topic/pfizer+inc..html"><![CDATA[Pfizer Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PFE</category>
		<category domain="tickers">BIIB,PFE</category>
	</item>
	<item>
		<title><![CDATA[Elan's Pennsylvania Lawyer Once Again Makes News]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000501/elans-pennsylvania-lawyer-once-again-makes-news/]]></link>
		<description><![CDATA[The pressure on Elan Pharmaceuticals CEO Kelly Martin to resign is increasing. Crabtree Partners, an investment company, sent a letter to Elan's board calling for the termination of Martin. But an interesting side-note in this soap opera is the history of Elan's general counsel, Richard Collier.    Crabtree...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Mon, 15 Dec 2008 12:38:28 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/pennsylvania.html"><![CDATA[Pennsylvania]]></category>
		<category domain="http://resources.bnet.com/topic/general+counsel.html"><![CDATA[General Counsel]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/crabtree.html"><![CDATA[Crabtree]]></category>
		<category domain="http://resources.bnet.com/topic/pharmacia.html"><![CDATA[Pharmacia]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+governance.html"><![CDATA[Corporate Governance]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/corporate+law.html"><![CDATA[Corporate Law]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
	</item>
	<item>
		<title><![CDATA[Pharma Roundup: Elan's Martin, Biotech's Worst CEO; Executive Shake-Up at Sanofi; and More]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000483/pharma-roundup-elans-martin-biotechs-worst-ceo-executive-shake-up-at-sanofi-and-more/]]></link>
		<description><![CDATA[Elan's Kelly Martin as biotech's worst CEO? Also, Sanofi's executive VP departs, biotechs seek federal aid, and Congress may debate potential DTC ban. by John Maas]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Wed, 10 Dec 2008 15:49:29 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/executive+vice+president.html"><![CDATA[Executive Vice President]]></category>
		<category domain="http://resources.bnet.com/topic/thestreet.com+inc..html"><![CDATA[TheStreet.com Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology.html"><![CDATA[Biotechnology]]></category>
		<category domain="http://resources.bnet.com/topic/taxes.html"><![CDATA[Taxes]]></category>
		<category domain="http://resources.bnet.com/topic/financial+planning.html"><![CDATA[Financial Planning]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[Finance]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
		<category domain="http://resources.bnet.com/topic/john+maas.html"><![CDATA[John Maas]]></category>
	</item>
	<item>
		<title><![CDATA[Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics]]></title>
		<link><![CDATA[http://www.bnet.com/5208-14054-0.html?forumID=1&threadID=3367&messageID=16025&start=0]]></link>
		<description><![CDATA[Wyeth, Elan and Bapineuzumab -- How to Lie With Drug StatisticsRE: Wyeth, Elan and Bapineuzumab -- How to Lie With Drug StatisticsLook at page 15 at a dose of 0.15 mg/kg for APOE4 carriers and page 17 at a dose of 0.5 mg/kg for APOE4 noncarriers.http://library.corporate-ir.net/library/88/883/88326/items/302302/ELNWYE20080729.pdfThose a trualy amazing numbers.How...]]></description>
		<s:doctype><![CDATA[Discussion threads]]></s:doctype>
		<pubDate>Mon, 08 Sep 2008 17:52:00 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/bapineuzumab.html"><![CDATA[Bapineuzumab]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Wyeth, Elan and Bapineuzumab -- How to Lie With (Drug) Statistics]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/1000148/wyeth-elan-and-bapineuzumab-the-folly-of-subgroup-analysis/]]></link>
		<description><![CDATA[In what is becoming a sadly common ritual, Wyeth and Elan are pressing forward with an expensive, large-scale "phase III" trial of a risky drug based on wishful thinking and shoddy statistical analysis.    The drug in question is bapineuzumab, a monoclonal antibody intended to treat Alzheimer's disease...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<pubDate>Tue, 29 Jul 2008 14:15:32 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/alzheimer%2527s+disease.html"><![CDATA[Alzheimer's Disease]]></category>
		<category domain="http://resources.bnet.com/topic/wyeth.html"><![CDATA[Wyeth]]></category>
		<category domain="http://resources.bnet.com/topic/patient.html"><![CDATA[Patient]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/david+p.+hamilton.html"><![CDATA[David P. Hamilton]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">WYE</category>
		<category domain="tickers">WYE</category>
	</item>
	<item>
		<title><![CDATA[Elan to Present at the Morgan Stanley Global Healthcare Unplugged Conference and Host Company Day]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2008_April_18/ai_n25335467]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Elan Corporation, plc (NYSE: ELN) today announced that it will present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1, 2008 at 11:20am EDT in Miami, Florida. Interested parties may access a live audio web cast of the presentation by visiting the Investor Relations...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 18 Apr 2008 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/conference.html"><![CDATA[conference]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/internet.html"><![CDATA[INTERNET]]></category>
		<category domain="http://resources.bnet.com/topic/morgan+stanley.html"><![CDATA[Morgan Stanley]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MS</category>
		<category domain="tickers">MS</category>
	</item>
	<item>
		<title><![CDATA[Elan Announces it will Present at the Goldman Sachs 28th Annual Global Healthcare Conference.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200705/ai_n19749312]]></link>
		<description><![CDATA[M2 PRESSWIRE-25 May 2007-News Flash: Elan Announces it will Present  at the Goldman Sachs 28th Annual Global Healthcare  ConferenceC1994-2007 M2 COMMUNICATIONS LTD    RDATE:25052007    Market Gainer is quickly emerging as the one stop shop for  international small-cap investors looking to stay a...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Fri, 25 May 2007 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/conference.html"><![CDATA[conference]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/goldman+sachs+group+inc..html"><![CDATA[Goldman Sachs Group Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/investor.html"><![CDATA[investor]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[security]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">GS</category>
		<category domain="tickers">GS</category>
	</item>
	<item>
		<title><![CDATA[Pantry Intends to Offer Notes to Buyers: DHPI, PTRY, LDG, ELN, BIIB.]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5243/is_200511/ai_n20044949]]></link>
		<description><![CDATA[M2 PRESSWIRE-15 November 2005-SessionsIR.com: Pantry Intends to  Offer Notes to Buyers: DHPI, PTRY, LDG, ELN, BIIBC1994-2005 M2  COMMUNICATIONS LTD    RDATE:15112005    Stocks in the News: Desert Health Products International  Incorporated (OTC: DHPI), Pantry Incorporated (NASDAQ: PTRY), Longs Drug  Stores Corporation (NYSE:...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 15 Nov 2005 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/benefits.html"><![CDATA[Benefits]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/groupware.html"><![CDATA[Groupware]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/nasdaq+stock+market+inc..html"><![CDATA[Nasdaq Stock Market Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/nyse+euronext.html"><![CDATA[NYSE Euronext]]></category>
		<category domain="http://resources.bnet.com/topic/pantry+inc..html"><![CDATA[Pantry Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/software.html"><![CDATA[SOFTWARE]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">NDAQ</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">PTRY</category>
		<category domain="tickers">BIIB,NDAQ,PTRY</category>
	</item>
	<item>
		<title><![CDATA[Elan reveals favourable drug trials for key MS drug]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_kmafp/is_200510/ai_n15701863]]></link>
		<description><![CDATA[LONDON AFP &#8212; Irish pharmaceuticals giant Elan said that the latest tests on patients receiving its multiple sclerosis drug Tysabri resulted in no new cases of a rare and frequently fatal infection.  Tysabri, made by the Irish drugs firm and US partner Biogen, was withdrawn in February after confirmed...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Mon, 17 Oct 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/agence+france-presse.html"><![CDATA[Agence France-Presse]]></category>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/infection.html"><![CDATA[infection]]></category>
		<category domain="http://resources.bnet.com/topic/microsoft+corp..html"><![CDATA[Microsoft Corp.]]></category>
		<category domain="http://resources.bnet.com/topic/security.html"><![CDATA[SECURITY]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="http://rss.financialcontent.com/stocksymbol">MSFT</category>
		<category domain="tickers">BIIB,MSFT</category>
	</item>
	<item>
		<title><![CDATA[Elan Confirms SEC Probe]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_hb5089/is_200504/ai_n18497707]]></link>
		<description><![CDATA[O'Driscoll, Sean   Irish Voice   04-19-2005   IRISH medical company Elan has confirmed that that it is being investigated  by the Securities and Exchange Commission for possible insider trading.   The investigation, confirmed by the corporation this week, follows  complaints about alleged sales...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Tue, 19 Apr 2005 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biogen+idec+inc..html"><![CDATA[Biogen Idec Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[SALES]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">BIIB</category>
		<category domain="tickers">BIIB</category>
	</item>
	<item>
		<title><![CDATA[Elan Announces Completion of Offering of US$1.15 Billion Aggregate Principal Amount of Senior Notes]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Nov_17/ai_n6363225]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Elan Corporation, plc ("Elan") today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., have completed the previously announced offering of US$1.15 billion aggregate principal amount of Senior Notes.  Commenting on the completion of the offering, Shane Cooke, executive vice president...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Wed, 17 Nov 2004 23:59:59 -0800</pubDate>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/fda.html"><![CDATA[FDA]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[HEALTHCARE]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
	<item>
		<title><![CDATA[Elan Reports Third Quarter 2004 Financial Results]]></title>
		<link><![CDATA[http://findarticles.com/p/articles/mi_m0EIN/is_2004_Oct_28/ai_n6257306]]></link>
		<description><![CDATA[DUBLIN, Ireland -- Elan Corporation, plc today announced its third quarter 2004 results and provided a business update.  Commenting on Elan's business, Kelly Martin, Elan's president and chief executive officer, said, "All of our energies are focused on delivering our science to patients with unmet medical needs. Today, our...]]></description>
		<s:doctype><![CDATA[Research articles]]></s:doctype>
		<pubDate>Thu, 28 Oct 2004 23:59:59 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/company.html"><![CDATA[Company]]></category>
		<category domain="http://resources.bnet.com/topic/divestment.html"><![CDATA[divestment]]></category>
		<category domain="http://resources.bnet.com/topic/ebitda.html"><![CDATA[EBITDA]]></category>
		<category domain="http://resources.bnet.com/topic/elan.html"><![CDATA[Elan]]></category>
		<category domain="http://resources.bnet.com/topic/elan+corp.+plc..html"><![CDATA[Elan Corp. Plc.]]></category>
		<category domain="http://resources.bnet.com/topic/finance.html"><![CDATA[FINANCE]]></category>
		<category domain="http://resources.bnet.com/topic/recovery.html"><![CDATA[Recovery]]></category>
		<category domain="http://resources.bnet.com/topic/revenue.html"><![CDATA[revenue]]></category>
		<category domain="http://resources.bnet.com/topic/sec.html"><![CDATA[SEC]]></category>
		<category domain="http://resources.bnet.com/topic/settlement.html"><![CDATA[settlement]]></category>
		<category domain="http://resources.bnet.com/topic/.html"><![CDATA[]]></category>
	</item>
</channel>
</rss>
